Skip to content

Reference information only. Therapept does not sell peptides and does not provide medical advice.Research-use notice

Therapept

Reference

Compare peptides

Two to four compounds, field by field: identity, United States regulatory status, and what kinds of documents are on file. The table records differences. It does not rank them.

No winner, no score, no recommendation. Counts describe how many documents of each kind Therapept has indexed — not how well a compound works, and not how much has been published overall.

Link to this comparison: /compare?peptides=ghrp-2,ipamorelin,hexarelin

Side-by-side comparison of GHRP-2, Ipamorelin, Hexarelin
GHRP-2IpamorelinHexarelin
Identity
ClassGrowth hormone secretagogue; synthetic hexapeptide containing D-amino acids and 2-naphthylalanineGrowth hormone secretagogue; ghrelin receptor (GHS-R1a) agonist. Synthetic pentapeptide containing unnatural amino acidsGrowth hormone secretagogue; synthetic hexapeptide containing 2-methyl-D-tryptophan
Also listed asPralmorelin, KP-102, Growth hormone releasing peptide-2NNC 26-0161, Ipamorelin acetateExamorelin, EP-23905, MF-6003
Molecular formulaC45H55N9O6C38H49N9O5C47H58N12O6
Molecular weight818.0 g/mol711.9 g/mol887.0 g/mol
CAS158861-67-7170851-70-4140703-51-1
PubChem CID691824598316596918297
Sequence lengthDescribed structurally, not as a residue listDescribed structurally, not as a residue listDescribed structurally, not as a residue list
Data caveatPubChem's GHRP-6 record (CID 4345065) carries the synonym “GHRP-2 Acetate”. Full caveatNone recordedPubChem also lists CAS 208251-52-9, which resolves to several deposits whose formulas differ from the free base by one or three acetate equivalents. Full caveat
United States regulatory status
StatusFDA compounding Category 2FDA compounding Category 2No FDA-approved product
FDA applicationNone recordedNone recordedNone recorded
CompoundingOn FDA's active 503B Category 2 list for injectable and nasal routes (added 29 September 2023).On FDA's active 503B Category 2 list (added 29 September 2023).No FDA compounding entry recorded
WADANamed at S2.2.4 among GH-releasing peptides, as “GHRP-2 (pralmorelin)”. Prohibited at all times.Named at S2.2.4 among growth hormone secretagogues. Prohibited at all times; non-Specified.Named at S2.2.4 among GH-releasing peptides, as “examorelin (hexarelin)”. Prohibited at all times.
Research profile
Research purposeNo plain-English profile recordedSelective GH secretagogue pharmacologyNo plain-English profile recorded
Proposed mechanismNo plain-English profile recordedAgonist at the ghrelin receptor (GHS-R1a) on pituitary somatotrophs, producing growth-hormone release. It acts at a different receptor from GHRH analogues such as tesamorelin.No plain-English profile recorded
Human evidenceNo plain-English profile recordedNo approved product. Human data are early pharmacology rather than Phase 3 efficacy trials; Therapept indexes no approved label and no completed efficacy programme.No plain-English profile recorded
Evidence tierNo plain-English profile recordedPreclinical models; no human efficacy trial indexedNo plain-English profile recorded
Known safety concernsNo plain-English profile recorded
  • On FDA's Category 2 table for bulk substances that may present significant safety risks in compounding, with published immunogenicity and characterisation concerns.
  • Named on the WADA Prohibited List as a growth-hormone secretagogue.
  • Long-term endocrine effects of repeated use are not characterised in controlled trials.
No plain-English profile recorded
Evidence gapsNo plain-English profile recorded
  • Controlled human efficacy and safety data.
  • Whether receptor selectivity translates into a better clinical profile.
  • Any lawful supply chain for human use.
No plain-English profile recorded
Head-to-head evidenceNo plain-English profile recordedNo published head-to-head efficacy trial against tesamorelin or CJC-1295.No plain-English profile recorded
Named pathwaysNo plain-English profile recordedGhrelin receptor (GHS-R1a) · Pituitary GH release · IGF-1No plain-English profile recorded
Evidence on file
Records
Human-interventional records010
Human-observational records000
Animal records010
In-vitro records000
Reviews010
Regulatory documents020
Earliest indexedNot recorded1998Not recorded
Latest indexedNot recorded2026Not recorded

Every identity and regulatory value above is taken from the compound’s record, where its sources are listed. Evidence counts are derived from the published evidence file at build time. A missing class means no document of that kind is indexed — not that none exists.